|
| * |
|
Zmax is indicated for acute bacterial sinusitis (ABS) due to
Haemophilus influenzae, Moraxella catarrhalis, or
Streptococcus pneumoniae in patients appropriate for oral
therapy.1
|
| † |
|
Zmax is also indicated for community-acquired pneumonia (CAP)
due to Chlamydophila pneumoniae, Haemophilus
influenzae, Mycoplasma pneumoniae, or Streptococcus
pneumoniae in patients appropriate for oral
therapy.1
|
References
|
1.
|
|
Zmax® (azithromycin extended release) for oral
suspension Prescribing Information. Pfizer Inc, New York, NY.
August 2007.
|
|
2.
|
|
Drehobl MA, De Salvo MC, Lewis DE, Breen JD. Single-dose
azithromycin microspheres vs clarithromycin extended release for
the treatment of mild-to-moderate community-acquired pneumonia in
adults. Chest. 2005;128:2230-2237.
|
|
3.
|
|
Murray J, Emparanza P, Lesinskas E, Tawadrous M, Breen JD. Efficacy
and safety of a novel, single-dose azithromycin microsphere
formulation versus 10 days of levofloxacin for the treatment of
acute bacterial sinusitis in adults. Otolaryngol Head Neck
Surg. 2005;133:194-201.
|
|